8UTK
IL-23R minibinder - 23R-B04dslf02IB
Summary for 8UTK
Entry DOI | 10.2210/pdb8utk/pdb |
Descriptor | 23R-B04dslf02IB, 1-(2-METHOXY-ETHOXY)-2-{2-[2-(2-METHOXY-ETHOXY]-ETHOXY}-ETHANE, SULFATE ION, ... (5 entities in total) |
Functional Keywords | computational design, selective inhibitors, il-2 il-17 cytokines de novo protein, de novo protein |
Biological source | synthetic construct |
Total number of polymer chains | 2 |
Total formula weight | 13337.96 |
Authors | |
Primary citation | Berger, S.,Seeger, F.,Yu, T.Y.,Aydin, M.,Yang, H.,Rosenblum, D.,Guenin-Mace, L.,Glassman, C.,Arguinchona, L.,Sniezek, C.,Blackstone, A.,Carter, L.,Ravichandran, R.,Ahlrichs, M.,Murphy, M.,Pultz, I.S.,Kang, A.,Bera, A.K.,Stewart, L.,Garcia, K.C.,Naik, S.,Spangler, J.B.,Beigel, F.,Siebeck, M.,Gropp, R.,Baker, D. Preclinical proof of principle for orally delivered Th17 antagonist miniproteins. Cell, 2024 Cited by PubMed: 38936360DOI: 10.1016/j.cell.2024.05.052 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (1.94 Å) |
Structure validation
Download full validation report![Download](/newweb/media/icons/dl.png)
![Download](/newweb/media/icons/dl.png)